2021
DOI: 10.3389/fnagi.2021.711195
|View full text |Cite
|
Sign up to set email alerts
|

Current Nosology of Neural Autoantibody-Associated Dementia

Abstract: BackgroundThe detection of neural autoantibodies in patients with cognitive decline is an increasingly frequent phenomenon in memory clinics, and demanding as it does a specific diagnostic approach and therapeutic management, it deserves greater attention. It is this review’s aim to present the latest nosology of neural autoantibody-associated dementia.MethodsA specific literature research via PubMed was conducted to describe the nosology of neural autoantibody-associated dementia.ResultsAn autoimmune dementia… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

3
4

Authors

Journals

citations
Cited by 13 publications
(13 citation statements)
references
References 69 publications
0
13
0
Order By: Relevance
“…However, there have been no investigations addressing the progression of cognitive dysfunction in autoantibody-associated dementia compared to Alzheimer's dementia (AD). Recent individual case reports (5)(6)(7) and reviews (1,3) have postulated that rapidly progressing cognitive dysfunction associated with neural autoantibodies are a typical clinical manifestation of NABD. We thus conducted a pilot trial relying on retrospective data to identify whether progressing cognitive dysfunction is more prominent in NABD than in AD.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…However, there have been no investigations addressing the progression of cognitive dysfunction in autoantibody-associated dementia compared to Alzheimer's dementia (AD). Recent individual case reports (5)(6)(7) and reviews (1,3) have postulated that rapidly progressing cognitive dysfunction associated with neural autoantibodies are a typical clinical manifestation of NABD. We thus conducted a pilot trial relying on retrospective data to identify whether progressing cognitive dysfunction is more prominent in NABD than in AD.…”
Section: Introductionmentioning
confidence: 99%
“…Neural autoantibody-associated dementia (NABD) ( 1 , 2 ) is a disease entity whose incidence is rising through the identification of novel neural autoantibodies in relationship to a clinical phenotype characterized by initial cognitive impairment. Recent progress has been made in classifying NABD ( 2 4 ).…”
Section: Introductionmentioning
confidence: 99%
“…Concurring with these signs of neurodegeneration in brain MRI, our CSF results deliver support, as we detected axonal degeneration in 75% via elevated tau and tau 181 protein. Axonal neurodegeneration may coincide with autoantibody-associated cognitive decline (16). Verbal memory involvement, with particular focus on memory recall in our patient with glycine-receptor antibodies is highly likely, as glycine receptors are expressed in the hippocampus (17).…”
Section: Discussionmentioning
confidence: 74%
“…This process may lead to the emergence of immune cells producing Ab reacting to surface proteins of intact neurons and other brain cells, as well as peptides and proteins released after their pathological breakdown 38 - 40 . Such autoimmune reaction has been implicated in autoimmune response-related psychosis and schizophrenia 41 , 42 as well as neural autoantibody-associated dementias (NABD) with signs of axonal degeneration 43 , 44 . Quantitative analysis and profiling of Aabs targeting neuronal proteins, may, therefore, provide specific and instructive information on the onset, mechanisms, and severity of brain pathology.…”
Section: Biology Of Aabs With Relevance To Nddsmentioning
confidence: 99%